Eli Lilly expands early-access program for experimental obesity drug retatrutide

Eli Lilly announced it will broaden its early-access initiative for retatrutide, an investigational drug targeting obesity.

The company said the program will let additional patients apply for the drug before it receives formal regulatory approval, following a recent case where a 79-year-old patient received special access.

Retatrutide is still in development and has not been approved by the FDA, but the expanded access could provide treatment options for patients with severe obesity while clinical trials continue.

The move reflects Lilly’s effort to address the growing demand for obesity therapies, though the drug’s ultimate market prospects will depend on trial outcomes and regulatory review.